Background : The secosteroid 1K, 25-dihydroxyvitamin D 3 (1) has a wide variety of biological activities, which makes it a promising therapeutic agent for the treatment of cancer, psoriasis and osteoporosis. Insight into the structure^activity relationships of the A-ring of 1 is still needed to assist the development of more potent and selective analogues as candidate chemotherapeutic agents, as well as to define the molecular mode of action.
Synthesis and biological evaluation of all A-ring stereoisomers of 5,6-trans-2-methyl-1,25-dihydroxyvitamin D 3 and their 20- 
Introduction
The hormonally active form of vitamin D, 1K,25-dihydroxyvitamin D 3 (1, Fig. 1 ), dominates the cell cycle in many malignant cells, regulating proliferation, di¡erentia-tion and apoptosis, in addition to its classical role in calcium and phosphorus homeostasis [1] . Such a wide variety of activities has hampered the clinical application of 1 and has stimulated chemical and biological research to ¢nd analogues with selective activity pro¢les as candidate therapeutic agents, as well as to de¢ne its molecular mode of action [2] . Most of the biological activities of 1 are considered to be mediated by a ligand-inducible transcription factor, vitamin D receptor (VDR), which belongs to the nuclear receptor superfamily. The speci¢c interaction of ligands with the ligand binding domain (LBD) of VDR has been the focus of attention in recent years, since it triggers the whole sequence of actions. In order to investigate the structure^activity relationships for this interaction, a number of analogues have been synthesized and biologically evaluated [3] . For the reasons of synthetic convenience and for metabolic studies of the inactivation process, many of the analogues synthesized so far were altered in the side chain, providing useful analogues with high or selective activity. Among them, 20-epi-1K,25-dihydroxyvitamin D 3 is noteworthy due to its high activity in cell di¡erentiation with a relatively low calcemic e¡ect, having a clearly distinct biological pro¢le from its parent hormone 1 [4, 5] . This 20-epimerization, combined with other modi¢cations in the side chain, led to the highly potent cell di¡erentiation-inducing and immunosuppressive analogue, 20-epi-22-oxa-1K,25-dihydroxy-24,26,27-trihomovitamin D 3 (KH-1060) [4] .
The A-ring moiety of 1, which bears two critical hydroxyl groups on the six-membered ring, is of recent interest for metabolic studies as well as for synthesis of analogues [6] . The con¢gurations of the two hydroxyl groups on the A-ring in the natural hormone are 1K and 3L (vitamin D numbering system). Epimerization of either the 1-or 3-hydroxyl group results in a marked reduction of VDR binding activity [7] . Modi¢cation in the A-ring provided characteristic analogues, such as 2L-(3-hydroxypropoxy)-1K,25-dihydroxyvitamin D 3 (ED-71), which has a strong calcium-regulating activity and is considered a promising candidate for the treatment of osteoporosis [8, 42, 43] . A known geometric stereoisomer of 1, 5,6-trans-1K,25-dihydroxyvitamin D 3 (2, Fig. 1 ) [9] , in which the exocyclic 10(19) -methylene group appears to be transposed to position 4 in a formal sense, has become of interest in connection with the potent A-ring analogue, 1K,25-dihydroxy-19-norvitamin D 3 (3, Fig. 1 ) [10] . In addition, analogues with the 5,6-trans motif, in combination with 16-ene modi¢cation, were recently reported to be promising antiproliferative agents [11] .
Okamura et al. reported in 1974 that the A-ring of 1 is in a rapid equilibrium of two chair conformers, K-form and L-form, in which the C10(19) double bond is orientated above or below the diene plane of the C5^C6^C7^C8 diene, respectively, by de¢nition ( Fig. 2) [12, 13] . They proposed that the L-form, in which the 1K-hydroxyl group occupies the equatorial position, may be responsible for biological activity, based upon the results obtained with tachysterol and other related analogues [14] . On the other hand, recent studies of 19-nor analogues by DeLuca et al. implied that the axial orientation of the 1K-hydroxyl group would be necessary for biological activity of vitamin D compounds [15] .
In view of the results of A-ring modi¢cation stated above, as well as the conformation^activity relationships in the A-ring, we synthesized all eight possible A-ring diastereomers of 2-methyl-1,25-dihydroxyvitamin D 3 (4a^h, Fig. 3 ), demonstrating that the potency of the analogues varies depending upon the con¢gurations not only of the C1 and C3 hydroxyl groups, but also of the C2 methyl group [16^19]. In particular, 2K-methyl-1K,25-dihydroxyvitamin D 3 (4a) exhibited four-fold higher VDR a¤nity than 1, while its 2-epimer, 2L-methyl-1K,25-dihydroxyvitamin D 3 (4b) showed one-eighth of the a¤nity of 1. This simple A-ring modi¢cation yielded for the ¢rst time an analogue (4a), having the natural side chain of 1, with signi¢cantly higher VDR binding activity than the parent hormone. Our research on 2-methyl-20-epi analogues (5aĥ , Fig. 3 ) also revealed that the combination of 2K-methyl introduction and 20-epimerization resulted in exceptionally high potency: in the case of 5a, the 20-epimer of 4a, 12-fold higher in VDR binding, six-fold in in-vivo calciumregulating activity and 590-fold in HL-60 cell di¡erentia-tion-inducing activity [17^20]. Introduction of the 2-methyl group was shown to alter the conformational equilibria in the A-ring to a certain extent. However, such high VDR a¤nity following 2K-methyl substitution could not be explained by those conformational e¡ects alone.
In our present work, we have designed and synthesized all possible A-ring stereoisomers of 5,6-trans-2-methyl-1,25-dihydroxyvitamin D 3 (6a^h, Fig. 3 ) and their 20-epimers (7a^h, Fig. 3 ) as novel analogues with the 5,6-trans modi¢cation to gain further insight into the structure^ac-tivity relationships of the A-ring, as well as to investigate how these combinations a¡ect the biological activity pro¢les. We also conducted computational docking of the 2-methyl analogues to the LBD of VDR, based upon the recently solved X-ray crystal structure of a mutant VDR [21] in order to understand the signi¢cance of 2-methyl substitution on the A-ring, and we propose possible binding modes of the highly potent methyl analogues to VDR.
Results and discussion

Synthesis
The 5,6-trans analogues were synthesized from their 5,6-cis counterparts via the SO 2 adducts [22, 23] . Scheme 1 exempli¢es the synthesis of 5,6-trans-2L-methyl-1K,25-dihydroxyvitamin D 3 (6a) from the 5,6-cis isomer (4b). Treatment of 4b with SO 2 gave a 6-epimeric mixture of the adducts 8. Subsequent removal of SO 2 in 8 by thermolysis in the presence of NaHCO 3 a¡orded 6a in 66% yield (two steps). In the case of 6a, the 3L-hydroxyl, 2L-methyl and 1K-hydroxyl groups may function as pseudo 1K-hydroxyl, pseudo 2K-methyl and pseudo 3L-hydroxyl groups, respectively [14] . The 5,6-trans analogues 6b, 6c, 6d, 6e, 6f, 6g and 6h were synthesized via exactly the same sequence of reactions from their 5,6-cis counterparts 4a, 4f, 4e, 4d, 4c, 4h and 4g, respectively. The other 5,6-trans-20-epi analogues (7a^h) were synthesized from the corresponding 5,6-cis-20-epi analogues (5a^h) as described above for the 20-natural analogues. As a reference compound, 5,6-trans-1K,25-dihydroxyvitamin D 3 (2) was prepared and its molar absorptivity was determined [9] . The hyperchromic e¡ect and red shift observed in the UV spectrum of 2 compared to 1 can be explained in terms of the change of the triene structure. Our results are consistent with those for 5,6-trans-25-hydroxyvitamin D 3 [24] .
Conformational analysis
In order to gain information on A-ring conformationâ ctivity relationships, the solution conformations of the 5,6-trans analogues were examined by means of 1 H NMR analyses together with molecular mechanics calculation. Since the roles of the two hydroxyl groups at the C1 and C3 positions appear to be exchanged in the 5,6-trans analogues, the K-form and L-form are de¢ned as illustrated in Fig. 2 , in which the 3-hydroxyl group is axially or equatorially orientated, respectively, in the case of 2. Firstly, the conformation of 2 was analyzed by 1 H NMR using CDCl 3 as a solvent in comparison with 1. The conformational equilibrium of 1 was estimated to be a ratio of 45:55 in favor of the L-form from the vicinal coupling constant between H(3K)^H(4L) of 6.7 Hz by the method based upon the data reported for cyclohexanol protons (J axYax = 11.1 Hz, J eqYeq = 2.7 Hz) [25] , which is widely accepted for analysis of the A-ring of vitamin D compounds [26, 27] . In the case of 2, steric repulsion between H(7) and H(19E) in the 5,6-cis compounds is released and the C10(19) exomethylene and C5^C6^C7^C8 diene can approach planarity, which would result in the hyperchromic e¡ect and red shift observed in the UV spectrum of 2 compared to 1. However, the three vicinal coupling constants of H(1L)^H(2K), H(2L)^H(3K) and H(3K)^H(4L) in 2, 5.2 Hz, 8.1 Hz and 8.5 Hz, respectively, indicated that both K-and L-forms were involved in a ratio of 30:70.
On the basis of the results with 2, the 1 H NMR spectra of all the synthesized analogues (6a^h, 7a^h) were analyzed. The 1 H NMR spectra were taken in CDCl 3^D2 O to exclude the coupling of H(1) and H(3) with hydroxyl protons in these cases. Analyses of COSY and decoupling experiments allowed the assignment of all A-ring signals and coupling constants. There was no marked di¡erence in chemical shifts between each pair of the (20R)-and (20S)-isomers, except for the chemical shifts due to the 20-methyl groups. In every case, the A-ring is in an equilibrium between two chair conformations, the K-and L-forms (Fig. 4) , as we previously reported in the case of 5,6-cis analogues [19] . In the case of 1,3-anti diols (a, b, g and h), the chair conformers in which the 2-methyl group occupies the equatorial position are favored. On the other hand, the 1,3-syn diols (c, d, e and f) mainly exist in the chair forms in which the two hydroxyl groups are axially orientated, because of the intramolecular hydrogen bond. The equilibrium ratios shown in Fig. 4 were deduced from the vicinal coupling constants of H(1)^H(2), H(2)^H(3) and H(3)^H(4). Molecular mechanics calculation using MM2* was carried out using model compounds lacking the side chain. As expected, the two chair conformers involved were most stable in each case and the calculated values of energy di¡erence and equilibrium ratios at 25³C, shown in parentheses in Fig. 4 , are in good agreement with the experimental data.
The orientations of the two hydroxyl groups and the 2-methyl group a¡ect the equilibrium ratio of the 5,6-trans analogues, and as a result, the equilibrium is biased to various extents in a direction that depends upon the Aring stereochemistry. In the case of isomer a, the 2L-methyl substituent favored the K-form, whereas the 2K-methyl substituent of isomer b favored the L-form. DeLuca et al. obtained conformationally locked A-ring analogues by 2-methyl introduction into 19-nor analogues [15] . The 19-nor modi¢cation consists of not only deletion of the C10 (19) exomethylene group, but also introduction of two protons into the C10 position. They reported that 2K-methyl-1K,25-dihydroxy-19-norvitamin D 3 was essentially completely locked in the K-form, in which the 1K-hydroxyl group is in the axial position, while 2L-methyl-1K,25-dihydroxy-19-norvitamin D 3 was locked in the L-form. On the other hand, our data on the 5,6-trans-2-methyl analogues (6a^h, 7a^h), as well as the 5,6-cis counterparts (4a^h, 5aĥ
), show that 2-methyl introduction yields, instead of conformational lock, a mixture of chair conformers, since the native A-ring with the C10(19) exomethylene groups allow the axial 2-methyl orientation to a certain extent due to the planar sp 2 carbon at C10.
Biological evaluation
The biological activities of the synthesized analogues (6a^h, 7a^h) were assessed in comparison with those of the natural hormone 1, together with its 5,6-trans stereoisomer 2. The results are summarized in Table 1 (the potency of 1 was normalized to 100 in each biological test). The activities were highly dependent upon the stereochemistry not only in the A-ring, but also at C20 in the side chain. On the basis of our previous results with the 5,6-cis-2-methyl analogues, the present data indicate that the 5,6-trans modi¢cation acts as a simple transposition of the C10(19) exocyclic methylene group, and as a result, the roles of the two hydroxyl groups at the C1 and C3 positions appeared to be exchanged in the 5,6-trans-2-methyl analogues [16] [17] [18] [19] [20] , except for the case of vitamin D binding protein (DBP) binding. Thus, these hybrid modi¢cations yielded analogues with unique activity pro¢les.
In the VDR binding assay using bovine thymus [28] , 5,6-trans-1K,25-dihydroxyvitamin D 3 (2) showed a reduced a¤nity compared to 1 by approximately 100-fold [9] . In addition, 5,6-trans modi¢cation of the 2-methyl analogues resulted in a reduction of a¤nity compared to each structurally-related 5,6-cis counterpart; for example, 6a showed approximately 50-fold lower a¤nity than 4a [16^20]. Among the 5,6-trans-2-methyl analogues with natural (20R)-con¢guration (6a^h), those having the 3L-hydroxyl group (6a^d), which would act as a pseudo 1K-hydroxyl group, exhibited higher a¤nity compared to the corresponding 3-epimers (6e^h). Introduction of the 2L-methyl group into 2 to produce 6a elevated the VDR a¤nity by approximately 10-fold, while introduction of the 2K-methyl group to give 6b reduced the potency. Thus, as in the case of 2K-methyl introduction into 1K,25-dihydroxyvitamin D 3 (1), the pseudo 2K-methyl introduction into 5,6-trans-1K,25-dihydroxyvitamin D 3 (2), such as in 6a, enhanced the a¤nity to VDR. These results imply that 2-methyl substitution in`up' con¢gurations, irrespective of 5,6-trans or 5,6-cis arrangement, would play an important role in enhancing the VDR binding potency. Transposition of the C10(19) exomethylene group reduced the a¤nity, but seemed to have little e¡ect on the character of each substituent in the A-ring. Similar trends were found among the 20-epi analogues with (20S)-con¢guration. The rank order of the VDR a¤nity among the 20-epi analogues (7a^h) was essentially the same as observed among the (20R)-counterparts (6a^h). The VDR binding potency of 20-epi-1K,25-dihydroxyvitamin D 3 using bovine thymus in comparison with 1, normalized to 100, was estimated to be 400 by us [29] and 500 by others [5] . 20-Epimerization of each 5,6-trans-2-methyl isomer elevated the a¤nity by approximately 3^15-fold. Thus, 2-methyl introduction and 20-epimerization had additive e¡ects on the VDR binding potency.
In the DBP binding assay using rat serum [30] , the analogues having the 2K-methyl con¢guration showed higher a¤nity than the corresponding 2-epimers, and 20-epimerization of each isomer decreased the a¤nity. The strongest ligand to DBP among vitamin D metabolites was considered to be 25-hydroxyvitamin D 3 , and a 1K-hydroxyl group decreased the a¤nity to DBP [31] . In the case of 5,6-trans analogues, however, isomers having the 3L-hydroxyl group, which would act as a pseudo 1K-hydroxyl group, proved to be better binders than those having the 3K-hydroxyl group. The C10(19) exomethylene group of 5,6-trans isomers seems to play an important role in the DBP binding and di¡erentiates the roles of the two hydroxyl groups in the A-ring.
Cell di¡erentiation-inducing activity of the analogues towards HL-60 cells at 10 38 M was assessed in terms of expression of cell surface CD11b [32] . Fig. 5 indicates that the analogues 6a, 7a and 7b exhibited a potency comparable to or even higher than that of the natural hormone 1. It is noteworthy that 7e was signi¢cantly active in spite of having the 3K-hydroxyl con¢guration (i.e., the pseudo 1L-hydroxyl con¢guration), which should impart low or no activity. Recent studies of A-ring analogues, in particular combined with side chain modi¢cations, show that the transcriptional potency is sometimes elevated even when the VDR binding a¤nity is low [44] [45] [46] . In order to examine further the potency as di¡erentiators, the dose dependency of selected analogues, 2, 6a, 6b, 7a, 7b, 7c and 7e, was investigated (Fig. 6) . The data are summarized as relative potencies with respect to 1, de¢ned as 100, in Table 1 . The cell di¡erentiation-inducing potency of 5,6-trans-1K,25-dihydroxyvitamin D 3 2 was approximately half that of the natural hormone 1. The analogue 6a showed 2.4-fold higher activity than 1, whereas its 2-epimer, 6b, exhibited 7% of the activity of the natural hormone 1. The potency of the isomers 6a,b was enhanced by 20-epimerization, but to a lesser extent than in the case of 5,6-cis-2-methyl analogues [16^20]. Those results might be explained by a di¡erence in DBP binding, which is believed to correlate with availability of the compounds to target cells [31] . Among the four analogues with (20S)-con¢guration, 7a exhibited 3.3 times higher potency than the natural hormone 1. Epimerization of the C1, C2 or C3 substituent in 7a yields 7c, 7b and 7e, respectively, all of which showed similar cell di¡erentiation-inducing activity.
As regards the activity of 20-epi-1K,25-dihydroxyvitamin D 3 , epimerization of either the C1-or C3-hydroxyl group dramatically decreases cell di¡erentiation-inducing activity by 360 times for C1 and 17 times for C3 [29] . In the case of 5,6-trans-2-methyl analogues, however, the bene¢cial e¡ects of`up' methyl introduction seemed to be well retained irrespective of C1 or C3 stereochemistry, and as a result, both the 1-epimer (7c) and 3-epimer (7e) of 7a showed signi¢cant cell di¡erentiation-inducing activity (approximately one-third of the activity of the natural hormone 1).
Docking modes of the A-ring analogues to vitamin D receptor
Interaction of the side chains of vitamin D analogues with VDR is well documented, and Yamada et al. showed that potential side chain structures, as well as their functions, can be predicted by conformational analysis using molecular mechanics [33] . Molecular modeling studies of the LBD of human VDR have reinforced the above concept [34] . Furthermore, di¡erential interaction of compounds having the natural side chain and their 20-epimers has been demonstrated based upon the X-ray structures of mutant human VDR complexed with 20-epi analogues [35] . In contrast, little is known about the structure^activ-ity relationships of the A-ring, irrespective of 5,6-cis or 5,6-trans structure.
Besides the conformational problems in the A-ring, additional e¡ects of 2-methyl substitution, which gave the analogues characteristic activity pro¢les, appeared to exist. The present data on the 5,6-trans-2-methyl analogues (6aĥ , 7a^h) have shed some light on the signi¢cance of 2-methyl introduction. Among the epimeric pairs di¡ering only in the con¢guration at the C2 position, every 2L-methyl (i.e., pseudo 2K-methyl) analogue exhibited higher VDR binding potency than the corresponding 2K-methyl (i.e., pseudo 2L-methyl) analogue by 10^60-fold. This may mean that an`upper' methyl group plays an important role in elevation of the VDR binding potency.
The amino acid residues in the LBD of VDR are essentially conserved among mammals, including bovine, porcine and human. The recently solved X-ray crystal structure of a mutant human VDR complexed with 1 demonstrated that the A-ring of 1 was docked to the LBD of VDR in its L-form [21] . The equatorial 1K-hydroxyl group of 1 formed two hydrogen bonds with Ser-237(H3) and Arg-274(H5), while the axial 3L-hydroxyl (1) or the analogues (2, 6a, 6b, 7a, 7b, 7c, 7e) for 72 h. Cell di¡erentiation was assessed in terms of expression of CD11b. Vehicle average is denoted by a solid diamond on the y-axis. The data are summarized as relative potencies with respect to 1, de¢ned as 100, in Table 1 . group of 1 formed two hydrogen bonds with Ser-278(H5) and Tyr-143. Interestingly, the experimental data show that there is additional space near the C2 position, which could accommodate a rather bulky substituent. The cavity is long, reaching the surface of the receptor. In the vicinity of the C2 position in the A-ring, the natural hormone 1 is surrounded by hydrophobic amino acid residues, such as Leu-233(H3), Tyr-236(H3) and Phe-150.
Among the 5,6-cis analogues, 2L-methyl-1K,25-dihydroxyvitamin D 3 (4b), the A-ring of which mainly exists in the L-form, showed a slightly reduced VDR a¤nity [19] . The VDR binding potencies of 2L-alkyl-substituted analogues were reported by us and by others using bovine thymus VDR. The estimates for 2L-methyl-(4b), 2L-ethyland 2L-propyl-1K,25-dihydroxyvitamin D 3 , relative to 1 normalized to 100, are 13, 10 and 26, respectively [161 9, 36] . Since the natural ligand 1 was bound in its Lform with additional space near position 2, these 2L-substituted analogues would interact with the LBD of VDR in their L-forms with the 2L-substituents in the equatorial positions without unfavorable structural dispositions. Indeed, the VDR binding potency was essentially unaltered among those three analogues. Binding modes of the 2K-substituted 5,6-cis analogues, however, could di¡er from those of 2L-substituted analogues. We have synthesized a series of 2K-substituted analogues having various lengths of 2-alkyl, 2-(g-hydroxyalkyl) and 2-(g-hydroxyalkoxy) groups, and found that the 2K-substituted analogues with terminal hydroxyl groups exhibited a marked elevation in VDR binding potency [37, 38] . Due to the long 2K-substituent, the A-ring of 2K-(3-hydroxypropoxy)-1K,25-dihydroxyvitamin D 3 , which showed 1.8-fold higher VDR a¤nity than 1, would adopt the K-form to dock into the LBD of VDR, facilitating an additional hydrogen bond network involving its terminal hydroxyl group with Asp-144 and Tyr-236 [38] . This, combined with two other molecular modeling results on the LBD of VDR [34, 39] , may mean that vitamin D analogues could be accommodated in the LBD of the receptor in either K-or L-form. The 2K-methyl introduction into the A-ring of 1 (as in 4a), which favored the K-form, caused a marked elevation in VDR a¤nity [19] . The VDR binding potencies of 2K-methyl-(4a), 2K-ethyl-and 2K-propyl-1K,25-dihydroxyvitamin D 3 relative to 1 (normalized to 100) were estimated to be 400, 40 and 20, respectively, by using bovine thymus VDR [16^19,37]. These 2K-substituted analogues could interact with the LBD of VDR in their K-forms with the 2K substituents in the equatorial positions as stated above in the case of 2K-(3-hydroxypropoxy)-1K,25-dihydroxyvitamin D 3 . However, the VDR a¤nity of 2K-methyl-1K,25-dihydroxyvitamin D 3 (4a) was considerably high among the three analogues compared with the corresponding 2L-alkyl-substituted counterparts, each of which showed similar a¤nity. We speculated that 2K-methyl-1K,25-dihydroxyvitamin D 3 (4a) would bind to the LBD in its Lform, essentially retaining the hydrogen bond networks observed in the X-ray-solved structure of 1 in the receptor.
In this case, the axial 2K-methyl group would ¢t into thè upper' hydrophobic pocket. Molecular mechanics calculations based upon the X-ray crystal structure [21] support the above hypothesis. Fig. 7 depicts a superposition of 2K-methyl-1K,25-dihydroxyvitamin D 3 (4a) and the natural hormone (1) bound to the LBD of VDR. A noteworthy feature is the lipophilic extension of 4a provided by the axial 2K-methyl substituent which reaches closer to thè upper' lipophilic pocket formed by Leu-233(H3), Tyr-236(H3) and Phe-150, leading to enhanced interaction. The axial 2K-methyl group would be in the close vicinity of the aromatic amino acid residues Tyr-236(H3) and Phe-150, which suggests the involvement of CH/Z interaction [40] , in addition to the steric e¡ects. This binding mode provides a basis for the structure^activity relationships of the 2-methyl-substituted analogues.
The VDR binding potency of 5,6-trans-1K,25-dihydroxyvitamin D 3 (2) was reduced by approximately 100-fold in Fig. 8 . Overlay of the modeled VDR/5,6-trans-methyl-1K,25-dihydroxyvitamin D 3 (2; carbon atoms in yellow) complex with the VDR/1K,25-dihydroxyvitamin D 3 (1; carbon atoms in green) structure [21] in the LBD. Hydrogen bonds are drawn as dotted lines. Due to the transposed C10(19) exomethylene group, the A-ring of 2 would be forced outward by Cys-288, resulting in a less favorable binding mode in terms of the C1 and C3 hydroxyl groups. Of the 32 amino acid residues used for the calculation, only those in the close vicinity of the A-ring are included for clarity.
comparison with 1. This may be explained by unfavorable steric contacts of the transposed exomethylene group with the amino acid residues of the LBD of VDR. Superimposed docking models of 1 and 2 show that the C10 (19) exomethylene group of 2 approaches the side chain of Cys-288(L-sheet), which causes a signi¢cantly less favorable binding mode (Fig. 8) . In the case of 5,6-trans-2-methyl analogues, the axial 2-methyl group would contact the`upper' lipophilic pocket, which indeed resulted in an approximately 10-fold elevation of the VDR a¤nity as seen in 6a compared to 2. In this situation, the A-ring of 6a would adopt the L-form, retaining the hydrogen bond networks of 2 in terms of the equatorial 3-hydroxyl group and the axial 1-hydroxyl group. Among the 19-nor compounds, the VDR binding potency of 2K-methyl-1K,25-dihydroxy-19-norvitamin D 3 was reported to be 22, relative to 1 normalized to 100, and that of its 2-epimer, 2L-methyl-1K,25-dihydroxy-19-norvitamin D 3 , to be 2.6 by using porcine intestinal VDR [15] . Similarly, the axial 2-methyl substituent of 2K-methyl-1K,25-dihydroxy-19-norvitamin D 3 could interact with the`upper' lipophilic pocket. However, the lack of the C10(19) exomethylene group would make the A-ring of the 19-nor analogues rather compact and further intrusion into the bottom of the cavity might a¡ord alternative binding modes. Further studies are required to assess the binding modes of the 19-nor analogues, taking into account the water molecules involved in this cavity [41] .
Signi¢cance
All possible A-ring stereoisomers of 5,6-trans-2-methyl-1,25-dihydroxyvitamin D 3 (6a^h) and their 20-epimers (7a^h) were designed and e¤ciently synthesized. Biological evaluation of the 5,6-trans analogues revealed that pseudo 2K-methyl introduction into the parent 5,6-trans-1K,25-dihydroxyvitamin D 3 (2) enhanced the potency, as in the case of the 2K-methyl introduction into 1K,25-dihydroxyvitamin D 3 (1) , which reinforced the idea of a bene¢cial e¡ect of the`up' methyl introduction. The combined modi¢cation of pseudo 2K-methyl introduction and 20-epimerization had additive e¡ects on VDR binding activity. Transposition of the C10(19) exomethylene group, on the other hand, di¡erentially a¡ected DBP binding and HL-60 cell di¡erentiation-inducing activity of the 2-methyl analogues. Molecular docking studies of the analogues in the LBD of VDR based upon the recently solved X-ray crystal structure of mutant VDR suggested that the axial 2-methyl substituent would contact a hydrophobic region, resulting in enhanced interaction. The putative binding modes of the potent 2-methyl analogues well explained the results of biological evaluation of these analogues. These binding models should provide a new design concept for VDR ligands and stimulate structure^function studies focused upon the protein^ligand complex.
Materials and methods
Chemical synthesis
Melting points were determined by using a Yanagimoto hotstage melting point apparatus and are uncorrected. NMR spectra were recorded on a JEOL GSX-400 spectrometer. Chemical shifts are expressed in ppm relative to tetramethylsilane. Mass spectra (MS) and high-resolution mass spectra (HRMS) were recorded on a JMS-SX 102A. Infrared spectra were recorded on a Jasco FT/IR-8000 spectrometer and are expressed in cm 31 . Ultraviolet spectra were recorded with a Shimadzu UV-1600 spectrophotometer. Optical rotations were determined by using a Jasco DIP-370 digital polarimeter. Elemental analyses were carried out in the Microanalytical Laboratory, Faculty of Pharmaceutical Sciences, University of Tokyo, and were within 0.3% of the theoretical values.
(5E,7E)-(1S,3R
)-9,10-Seco-5,7,10(19)-cholestatriene-1,3,25-triol (2) (5Z,7E)-(1S,3R)-9,10-Seco-5,7,10(19)-cholestatriene-1,3,25-triol (1) (16.5 mg, 0.04 mmol) was dissolved in liquid SO 2 (V10 ml), and the solution was re£uxed at the boiling temperature of SO 2 for 30 min. After SO 2 was evaporated, the residue was dissolved in ethanol (2 ml), and NaHCO 3 (17 mg, 0.2 mmol) was added. The resulting mixture was heated at 90³C for 4 h. After the solvent was evaporated, brine was added to the mixture and the whole was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, ¢ltered and concentrated. The crude product was puri¢ed by silica gel preparative TLC (ethyl acetate) to give the vitamin (13.7 mg, 83%) as a white solid. Further puri¢cation was conducted using reversed-phase recycle HPLC (YMC-Pack ODS column, 20 mmU150 mm, 9.0 ml/min, acetonitrile :water = 8:2), followed by recrystallization from ethyl acetate to give analytically pure vitamin as colorless ¢ne prisms: mp 175^176³C (recryst. from ethyl acetate); [K] 
(5E,7E)-(1S,2R
,3R)-2-Methyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol (6a) (5Z,7E)-(1S,2R,3R)-2-Methyl-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol (4b) (7.0 mg, 0.016 mmol) was dissolved in liquid SO 2 (V10 ml), and the solution was re£uxed at the boiling temperature of SO 2 for 1 h. After SO 2 was evaporated, the residue was dissolved in ethanol (2 ml), and NaHCO 3 (6.8 mg, 0.081 mmol) was added. The resulting mixture was heated at 90³C for 1 h. After the solvent was evaporated, brine was added to the mixture and the whole was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, ¢ltered and concentrated. The crude product was puri¢ed by silica gel preparative TLC (ethyl acetate) to give 6a (4.6 mg, 66%) as a colorless solid. Further puri¢cation for biological evaluation was conducted by using reversed-phase recycle HPLC (YMC-Pack ODS column, 20 mmU150 mm, 9.0 ml/min, acetonitrile:water = 8: 
. Conformational analysis
The A-ring conformations of the vitamin D analogues were calculated using model compounds lacking the side chain at C22 by MacroModel1 version 6.5 (Schroedinger) on a Silicon Graphics O2 workstation. Conformational search was performed with the Monte Carlo method of MacroModel1.
Docking studies
The coordinates of mutant human VDR complexed to 1 were taken from the Brookhaven Protein Data Bank (PDB code 1DB1) and hydrogen atoms were added computationally at appropriate positions. The following 32 amino acid residues in the LBD, which are in the vicinity of 1, were used for the calculation: Tyr-143, Asp-144, Tyr-147, Asp-149, Phe-150, Leu-227, Leu-230, Leu-233, Val-234, Tyr-236, Ser-237, Ile-268, Ile-271, Met-272, Arg-274, Ser-275, Ser-278, Trp-286, Cys-288, Tyr-293, Tyr-295, Val-300, Ala-303, His-305, Leu-309, Leu-313, His-397, Tyr-401, Leu-404, Leu-414, Val-418 and Phe-422. The residues were constrained with a force constant of 100.0 kJ. Structures of vitamin D analogues bound to VDR were constructed by molecular dynamics (MD) simulation and molecular mechanics (MM) energy minimization. The starting position of the ligand was determined manually: the A-ring moiety of the ligand was superimposed onto its crystallographic counterpart of 1 in the LBD. MD simulation was performed during 10 ps at 300 K. A hundred structures sampled from MD simulation were minimized by MM calculation based upon the AMBER* force ¢eld. MD simulation performed during 100 ps at 3000 K, with a force constant of 10 000 kJ, gave similar results. All calculations were performed by MacroModel1 version 6.5 (Schroedinger) on a Silicon Graphics O2 workstation.
